• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现不对称芳基二硫化物作为新型严重急性呼吸综合征冠状病毒主要蛋白酶抑制剂:化学合成、生物学评价、分子对接和三维定量构效关系研究

Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.

作者信息

Wang Li, Bao Bo-Bo, Song Guo-Qing, Chen Cheng, Zhang Xu-Meng, Lu Wei, Wang Zefang, Cai Yan, Li Shuang, Fu Sheng, Song Fu-Hang, Yang Haitao, Wang Jian-Guo

机构信息

State-Key Laboratory and Research Institute of Elemento-Organic Chemistry, National Pesticide Engineering Research Center, College of Chemistry, Nankai University, Tianjin 300071, China.

School of Life Sciences, Tianjin University, Tianjin 300072, China; Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin 300457, China.

出版信息

Eur J Med Chem. 2017 Sep 8;137:450-461. doi: 10.1016/j.ejmech.2017.05.045. Epub 2017 Jun 9.

DOI:10.1016/j.ejmech.2017.05.045
PMID:28624700
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7115414/
Abstract

The worldwide outbreak of severe acute respiratory syndrome (SARS) in 2003 had caused a high rate of mortality. Main protease (M) of SARS-associated coronavirus (SARS-CoV) is an important target to discover pharmaceutical compounds for the therapy of this life-threatening disease. During the course of screening new anti-SARS agents, we have identified that a series of unsymmetrical aromatic disulfides inhibited SARS-CoV M significantly for the first time. Herein, 40 novel unsymmetrical aromatic disulfides were synthesized chemically and their biological activities were evaluated in vitro against SARS-CoV M. These novel compounds displayed excellent IC data in the range of 0.516-5.954 μM. Preliminary studies indicated that these disulfides are reversible and mpetitive inhibitors. A possible binding mode was generated via molecular docking simulation and a comparative field analysis (CoMFA) model was constructed to understand the structure-activity relationships. The present research therefore has provided some meaningful guidance to design and identify anti-SARS drugs with totally new chemical structures.

摘要

2003年严重急性呼吸综合征(SARS)在全球范围内爆发,导致了很高的死亡率。严重急性呼吸综合征冠状病毒(SARS-CoV)的主要蛋白酶(M)是发现用于治疗这种危及生命疾病的药物化合物的重要靶点。在筛选新型抗SARS药物的过程中,我们首次发现一系列不对称芳基二硫化物能显著抑制SARS-CoV M。在此,通过化学合成了40种新型不对称芳基二硫化物,并在体外评估了它们对SARS-CoV M的生物活性。这些新型化合物的IC数据优异,范围在0.516 - 5.954μM之间。初步研究表明,这些二硫化物是可逆的竞争性抑制剂。通过分子对接模拟生成了一种可能的结合模式,并构建了比较分子场分析(CoMFA)模型以了解构效关系。因此,本研究为设计和鉴定具有全新化学结构的抗SARS药物提供了一些有意义的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/c51dd7d5eb42/sc2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/a1c955b7f76f/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/c72ebde1f115/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/605c71fe179b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/845c3ed72c17/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/783bfea64664/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/ae1d2dd5bbe1/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/10c45e56576a/sc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/c51dd7d5eb42/sc2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/a1c955b7f76f/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/c72ebde1f115/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/605c71fe179b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/845c3ed72c17/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/783bfea64664/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/ae1d2dd5bbe1/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/10c45e56576a/sc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/c51dd7d5eb42/sc2_lrg.jpg

相似文献

1
Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.发现不对称芳基二硫化物作为新型严重急性呼吸综合征冠状病毒主要蛋白酶抑制剂:化学合成、生物学评价、分子对接和三维定量构效关系研究
Eur J Med Chem. 2017 Sep 8;137:450-461. doi: 10.1016/j.ejmech.2017.05.045. Epub 2017 Jun 9.
2
Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease.基于结构的设计、合成及一系列新型、可逆的严重急性呼吸综合征冠状病毒木瓜蛋白酶样蛋白酶抑制剂的生物学评价。
J Med Chem. 2009 Aug 27;52(16):5228-40. doi: 10.1021/jm900611t.
3
Inhibitor design for SARS coronavirus main protease based on "distorted key theory".基于“扭曲钥匙理论”的严重急性呼吸综合征冠状病毒主要蛋白酶抑制剂设计
Med Chem. 2007 Jan;3(1):1-6. doi: 10.2174/157340607779317616.
4
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.强效SARS-CoV 3CL(蛋白酶)抑制剂的设计、合成及生物学评价的新进展
Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7. doi: 10.1016/j.bmcl.2009.03.118. Epub 2009 Mar 28.
5
Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.辛那色林是严重急性呼吸综合征冠状病毒3C样蛋白酶的抑制剂,在体外能强烈降低病毒复制。
J Virol. 2005 Jun;79(11):7095-103. doi: 10.1128/JVI.79.11.7095-7103.2005.
6
Drug design targeting the main protease, the Achilles' heel of coronaviruses.针对主要蛋白酶的药物设计,冠状病毒的致命弱点。
Curr Pharm Des. 2006;12(35):4573-90. doi: 10.2174/138161206779010369.
7
Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.针对严重急性呼吸综合征3CL蛋白酶的强效酰苯胺类抑制剂的发现。
J Med Chem. 2005 Jun 30;48(13):4469-73. doi: 10.1021/jm050184y.
8
Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.通过虚拟筛选和3D-QSAR研究发现新型SARS-CoV蛋白酶抑制剂家族。
J Med Chem. 2006 Jun 15;49(12):3485-95. doi: 10.1021/jm050852f.
9
Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.基于结构的严重急性呼吸综合征冠状病毒主要蛋白酶新型非肽抑制剂的药物设计与结构生物学研究
J Med Chem. 2006 Aug 24;49(17):5154-61. doi: 10.1021/jm060207o.
10
Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.一系列丝氨酸衍生物作为严重急性呼吸综合征冠状病毒3CL蛋白酶小分子抑制剂的设计与合成
Bioorg Med Chem. 2016 Mar 15;24(6):1241-54. doi: 10.1016/j.bmc.2016.01.052. Epub 2016 Jan 29.

引用本文的文献

1
Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach.靶向严重急性呼吸综合征冠状病毒2主蛋白酶:一种药效团和分子建模方法。
J Mol Model. 2025 Jul 29;31(8):222. doi: 10.1007/s00894-025-06441-5.
2
Synthesis and Biological Activity of Glycosyl Thiazolyl Disulfides Based on Thiacarpine, an Analogue of the Cytotoxic Alkaloid Polycarpine from the Ascidian .基于硫卡品(一种来自海鞘的细胞毒性生物碱多卡品的类似物)的糖基噻唑基二硫化物的合成及生物活性
Mar Drugs. 2025 Mar 9;23(3):117. doi: 10.3390/md23030117.
3
Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors.

本文引用的文献

1
Discovery of a novel covalent non-β-lactam inhibitor of the metallo-β-lactamase NDM-1.新型金属β-内酰胺酶NDM-1共价非β-内酰胺抑制剂的发现
Bioorg Med Chem. 2016 Jul 1;24(13):2947-2953. doi: 10.1016/j.bmc.2016.04.064. Epub 2016 May 2.
2
Crystal Structure of Feline Infectious Peritonitis Virus Main Protease in Complex with Synergetic Dual Inhibitors.猫传染性腹膜炎病毒主要蛋白酶与协同双抑制剂复合物的晶体结构
J Virol. 2015 Dec 9;90(4):1910-7. doi: 10.1128/JVI.02685-15. Print 2016 Feb 15.
3
A Structure Guided QSAR: A Rapid and Accurate technique to predict IC50: A Case Study.
针对 SARS-CoV-2 主蛋白酶前体 N 端自我加工的创新抗病毒药物的分析方法开发与验证。
Viruses. 2024 Jul 29;16(8):1218. doi: 10.3390/v16081218.
4
3-chymotrypsin-like protease in SARS-CoV-2.SARS-CoV-2 中的 3-糜蛋白酶样蛋白酶。
Biosci Rep. 2024 Aug 28;44(8). doi: 10.1042/BSR20231395.
5
The effect of Phytopaj L. oleo gum resin and tragacanth( in patients with COVID-19: A randomized clinical trial.植妥帕(Phytopaj)(阿魏油胶树脂和黄芪胶)对新冠肺炎患者的影响:一项随机临床试验
Avicenna J Phytomed. 2024 Mar-Apr;14(2):152-165. doi: 10.22038/AJP.2023.22800.
6
Consensus Pharmacophore Strategy For Identifying Novel SARS-Cov-2 M Inhibitors from Large Chemical Libraries.从大型化学文库中鉴定新型 SARS-CoV-2 M 抑制剂的共识药效团策略。
J Chem Inf Model. 2024 Mar 25;64(6):1984-1995. doi: 10.1021/acs.jcim.3c01439. Epub 2024 Mar 12.
7
Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors.SARS-CoV-2 蛋白酶抑制剂的筛选、合成和生化特性分析。
Int J Mol Sci. 2023 Aug 30;24(17):13491. doi: 10.3390/ijms241713491.
8
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用:全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
9
A Tale of Two Proteases: M and TMPRSS2 as Targets for COVID-19 Therapies.两种蛋白酶的故事:M和跨膜丝氨酸蛋白酶2作为新冠病毒疗法的靶点
Pharmaceuticals (Basel). 2023 Jun 2;16(6):834. doi: 10.3390/ph16060834.
10
QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease.关于设计严重急性呼吸综合征冠状病毒主要蛋白酶强效抑制剂的定量构效关系和分子对接研究。
Front Pharmacol. 2023 May 5;14:1185004. doi: 10.3389/fphar.2023.1185004. eCollection 2023.
一种基于结构的定量构效关系:预测半数抑制浓度(IC50)的快速准确技术:案例研究
Curr Comput Aided Drug Des. 2015;11(2):152-63. doi: 10.2174/1573409911666150702100839.
4
Comparative evaluation of several docking tools for docking small molecule ligands to DC-SIGN.几种将小分子配体对接至DC-SIGN的对接工具的比较评估
J Mol Model. 2015 Jun;21(6):164. doi: 10.1007/s00894-015-2713-2. Epub 2015 Jun 4.
5
Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.5-磺酰基异吲哚酮衍生物作为严重急性呼吸综合征冠状病毒3C样蛋白酶抑制剂的合成、修饰及对接研究
Bioorg Med Chem. 2014 Jan 1;22(1):292-302. doi: 10.1016/j.bmc.2013.11.028. Epub 2013 Nov 21.
6
Targeting of arenavirus RNA synthesis by a carboxamide-derivatized aromatic disulfide with virucidal activity.靶向具有病毒灭活活性的芳基二硫化物羧酰胺衍生物的沙粒病毒 RNA 合成。
PLoS One. 2013 Nov 20;8(11):e81251. doi: 10.1371/journal.pone.0081251. eCollection 2013.
7
Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies.新型 P3 骨架的强效二肽型 SARS-CoV 3CL 蛋白酶抑制剂的研发:设计、合成、生物评价和对接研究。
Eur J Med Chem. 2013 Oct;68:372-84. doi: 10.1016/j.ejmech.2013.07.037. Epub 2013 Aug 9.
8
Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: structure-activity relationship study.新型二肽型 SARS-CoV 3CL 蛋白酶抑制剂的设计、合成与生物评价:构效关系研究。
Eur J Med Chem. 2013 Jul;65:436-47. doi: 10.1016/j.ejmech.2013.05.005. Epub 2013 May 20.
9
Synthesis and biological evaluation of nonsymmetrical aromatic disulfides as novel inhibitors of acetohydroxyacid synthase.不对称芳香二硫醚的合成及其作为新型乙酰羟酸合酶抑制剂的生物评价。
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3723-7. doi: 10.1016/j.bmcl.2013.05.013. Epub 2013 May 16.
10
Selective inhibition of extracellular thioredoxin by asymmetric disulfides.不对称二硫化物对细胞外硫氧还蛋白的选择性抑制。
J Med Chem. 2013 Feb 14;56(3):1301-10. doi: 10.1021/jm301775s. Epub 2013 Jan 31.